Alnylam Pharmaceuticals (ALNY) Stock Chart & Stock Price History $320.52 -0.01 (0.00%) Closing price 07/21/2025 04:00 PM EasternExtended Trading$320.72 +0.20 (+0.06%) As of 07/21/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Alnylam Pharmaceuticals Stock Price Performance The Alnylam Pharmaceuticals (ALNY) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 36.05%, with a year-to-date return of 36.21%. In the past month, the stock has increased 3.49%, reflecting recent market activity. As of the latest close, Alnylam Pharmaceuticals traded at $320.52 with a market cap of $41.79 billion and volume of 744,525 shares. Five years ago, the stock traded at $157.98, representing a 102.89% increase over that period. At the time, it had a market cap of $18.23 billion and a volume of 363,300 shares. Receive ALNY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-1.28%1 Month Performance+3.49%3 Month Performance+35.38%Year-To-Date Performance+36.21%1 Year Performance+36.05%5 Year Performance+102.89% ALNY Stock Chart for Tuesday, July, 22, 2025 ALNY Chart by TradingView Alnylam Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/21/2025$320.53$320.520.00%$328.70$320.26744,525 shs$41.79 billion07/18/2025$324.69$320.53-1.28%$325.62$317.88581,322 shs$41.79 billion07/17/2025$322.81$324.69+0.58%$329.87$321.06744,559 shs$42.34 billion07/16/2025$311.12$322.81+3.76%$323.41$311.261.23 million shs$42.09 billion07/15/2025$315.75$311.12-1.47%$316.90$309.57927,235 shs$40.57 billion07/14/2025$314.94$315.75+0.26%$319.18$313.76629,558 shs$41.17 billion07/11/2025$322.64$314.94-2.39%$321.12$312.961.08 million shs$41.07 billion07/10/2025$320.87$322.64+0.55%$324.82$319.15489,398 shs$42.07 billion07/09/2025$317.50$320.87+1.06%$322.68$313.741.04 million shs$41.84 billion07/08/2025$324.13$317.50-2.05%$328.99$315.81972,968 shs$41.40 billion Get the Latest News and Ratings for ALNY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/07/2025$331.94$324.13-2.35%$328.24$314.101.29 million shs$42.26 billion07/04/2025$331.94$331.94$333.70$327.88431,157 shs$43.28 billion07/03/2025$329.77$331.94+0.66%$333.70$327.88431,157 shs$43.28 billion07/02/2025$322.06$329.77+2.39%$330.00$319.40967,737 shs$43.00 billion07/01/2025$326.09$322.06-1.24%$326.64$315.031.24 million shs$41.99 billion06/30/2025$322.83$326.09+1.01%$327.21$320.57943,507 shs$42.52 billion06/27/2025$318.25$322.83+1.44%$323.20$315.142.05 million shs$42.09 billion06/26/2025$321.94$318.25-1.15%$325.00$315.00663,904 shs$41.50 billion06/25/2025$325.00$321.94-0.94%$324.32$320.71632,571 shs$41.98 billion06/24/2025$313.13$325.00+3.79%$326.03$309.961.00 million shs$42.38 billion06/23/2025$309.70$313.13+1.11%$314.78$308.46503,129 shs$40.83 billion06/20/2025$312.32$309.70-0.84%$314.50$308.781.34 million shs$40.38 billion Related Companies Amgen Stock Price Chart Gilead Sciences Stock Price Chart Vertex Pharmaceuticals Stock Price Chart Regeneron Pharmaceuticals Stock Price Chart Biogen Stock Price Chart Incyte Stock Price Chart United Therapeutics Stock Price Chart Neurocrine Biosciences Stock Price Chart Exelixis Stock Price Chart BioMarin Pharmaceutical Stock Price Chart Receive ALNY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ALNY) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
